ADAR1 Capital Management, LLC
Institutional InvestorSimilar funds →SEC EDGAR: CIK 1940272
Institutional-grade research for retail investors
Email me the moment this fund files its next 13F
13F Reported Value
ⓘ$2.2B
incl. option notional
Equity Holdings
ⓘ$2.1B
Option Notional
ⓘ$57.7M
$48.8M puts / $8.8M calls
Holdings
277
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
ADAR1 Capital Management, LLC disclosed 277 positions worth $2.2B in its Form 13F-HR for Q2 2026 — $2.1B in common stock plus $57.7M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ABVX (Abivax S.A.) at 11.3% of the equity portfolio, followed by $PTGX and $ROIV. During the quarter the fund opened 43 new positions and exited 76 — including a new stake in $EDIT and a full exit from $TERN. The portfolio is most concentrated in Healthcare (88.3% of disclosed assets). All figures are sourced directly from ADAR1 Capital Management, LLC’s Form 13F-HR filing with the SEC under CIK 1940272.
AI Fund Analysis
ConcentratingSector Allocation
HealthcareOtherFinancialsTechnologyConsumer StaplesReal Estate
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
ISHARES TR - RUSSELL 2000 ETFPUT$19M notional
$SPYPUT$19M notional
SPDR SERIES TRUST - ST STR SP BIOTPUT$11M notional
$ABVXCALL$6M notional
$KVACCALL$930K notional
$AMLXPUT$720K notional
$RARECALL$668K notional
$NVOCALL$623K notional
$CRBPCALL$563K notional
$STICALL$125K notional
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
AI Quality Scored
- —
Quality
$240.5M1,804,703 sh - 59.4#931
Quality
$117.8M960,863 sh - —
Quality
$111.7M3,157,008 sh - —
Quality
$96.4M129,087 sh - —
Quality
$89.8M2,330,716 sh - —
Quality
$64.0M3,369,034 sh - 26.9
Quality
$47.8M1,288,053 sh - 25.5
Quality
$45.7M1,222,080 sh EA SERIES TRUST - ALPHA ARCH 1-3
—Quality
$39.5M337,125 sh- 28.1
Quality
$39.0M457,907 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Abivax S.A.$ABVX | — | $240.5M | 1,804,703 |
 Protagonist Therapeutics, Inc$PTGX | 59.4#931 | $117.8M | 960,863 |
 Roivant Sciences Ltd.$ROIV | — | $111.7M | 3,157,008 |
 SPDR S&P 500 ETF TRUST$SPY | — | $96.4M | 129,087 |
 Immunovant, Inc.$IMVT | — | $89.8M | 2,330,716 |
 Zai Lab Ltd$ZLAB | — | $64.0M | 3,369,034 |
 AGIOS PHARMACEUTICALS, INC.$AGIO | 26.9 | $47.8M | 1,288,053 |
 Crinetics Pharmaceuticals, Inc.$CRNX | 25.5 | $45.7M | 1,222,080 |
| EA SERIES TRUST - ALPHA ARCH 1-3 | — | $39.5M | 337,125 |
 CYTOKINETICS INC$CYTK | 28.1 | $39.0M | 457,907 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of ADAR1 Capital Management, LLC's 277 positions.
Showing top 10 of 277 holdings.
Sector Allocation
Healthcare
$1.9B
Other
$201.1M
Financials
$36.4M
Technology
$7.2M
Consumer Staples
$1.9M
Real Estate
$1.0M
Industrials
$995,152
Consumer Discretionary
$611,734
Full Holdings — ADAR1 Capital Management, LLC (Q2 2026)
All 277 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ABVX | Abivax S.A. | $240.5M | 11.3% | +29% | — |
| 2 | $PTGX | Protagonist Therapeutics, Inc | $117.8M | 5.5% | -3% | 59.4 |
| 3 | $ROIV | Roivant Sciences Ltd. | $111.7M | 5.3% | -4% | — |
| 4 | $SPY | SPDR S&P 500 ETF TRUST | $96.4M | 4.5% | +70% | — |
| 5 | $IMVT | Immunovant, Inc. | $89.8M | 4.2% | -13% | — |
| 6 | $ZLAB | Zai Lab Ltd | $64.0M | 3.0% | +136% | — |
| 7 | $AGIO | AGIOS PHARMACEUTICALS, INC. | $47.8M | 2.3% | +816% | 26.9 |
| 8 | $CRNX | Crinetics Pharmaceuticals, Inc. | $45.7M | 2.1% | +7% | 25.5 |
| 9 | — | EA SERIES TRUST - ALPHA ARCH 1-3 | $39.5M | 1.9% | +0% | — |
| 10 | $CYTK | CYTOKINETICS INC | $39.0M | 1.8% | -28% | 28.1 |
| 11 |  $SEPN | Septerna, Inc. | $31.5M | 1.5% | -14% | 59.2 |
| 12 |  $AVR | Anteris Technologies Global Corp. | $31.0M | 1.5% | -17% | — |
| 13 |  $EDIT | Editas Medicine, Inc. | $28.8M | 1.4% | NEW | 33.4 |
| 14 |  $DNLI | Denali Therapeutics Inc. | $26.5M | 1.2% | -45% | — |
| 15 |  $SYRE | Spyre Therapeutics, Inc. | $25.2M | 1.2% | -16% | — |
| 16 |  $VIR | Vir Biotechnology, Inc. | $25.0M | 1.2% | -10% | 38.2 |
| 17 |  $PRAX | Praxis Precision Medicines, Inc. | $24.9M | 1.2% | +4850% | — |
| 18 |  $INSM | INSMED Inc | $24.4M | 1.1% | +546% | 39.4 |
| 19 |  $CLDX | Celldex Therapeutics, Inc. | $23.1M | 1.1% | +45% | 8.4 |
| 20 |  $VKTX | Viking Therapeutics, Inc. | $22.4M | 1.1% | +152% | — |
| 21 |  $TSHA | Taysha Gene Therapies, Inc. | $20.7M | 1.0% | +2% | 4.9 |
| 22 |  $MNPR | Monopar Therapeutics | $20.1M | 0.9% | -18% | — |
| 23 |  $OVID | Ovid Therapeutics Inc. | $20.0M | 0.9% | +63% | 26.4 |
| 24 |  $ELVN | Enliven Therapeutics, Inc. | $19.7M | 0.9% | +18% | — |
| 25 |  $ENTA | ENANTA PHARMACEUTICALS INC | $19.6M | 0.9% | +2518% | 17.8 |
| 26 | — | ISHARES TR - RUSSELL 2000 ETF | $18.8M | — | +127% | — |
| 27 | $SPYPUT | SPDR S&P 500 ETF TRUST | $18.7M | — | NEW | — |
| 28 |  $NKTR | NEKTAR THERAPEUTICS | $17.0M | 0.8% | +51% | 9.7 |
| 29 |  $INSP | Inspire Medical Systems, Inc. | $16.7M | 0.8% | -8% | 63.7 |
| 30 |  $RVMD | Revolution Medicines, Inc. | $16.4M | 0.8% | -35% | — |
| 31 |  $ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $15.9M | 0.8% | -13% | 33.9 |
| 32 | — | PROTHENA CORP PLC - SHS | $15.2M | 0.7% | -2% | — |
| 33 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $15.1M | 0.7% | -36% | 33.9 |
| 34 |  $IKT | Inhibikase Therapeutics, Inc. | $15.0M | 0.7% | +12% | — |
| 35 |  $QURE | uniQure N.V. | $15.0M | 0.7% | +326% | — |
| 36 |  $RLYB | Rallybio Corp | $14.8M | 0.7% | +4411% | — |
| 37 |  $REGN | REGENERON PHARMACEUTICALS, INC. | $13.8M | 0.7% | +83% | 71 |
| 38 |  $IVA | Inventiva S.A. | $13.6M | 0.6% | +66% | — |
| 39 |  $STRO | SUTRO BIOPHARMA, INC. | $13.4M | 0.6% | -23% | 15.3 |
| 40 |  $IONS | IONIS PHARMACEUTICALS INC | $13.2M | 0.6% | +4% | 23.4 |
| 41 |  $BBIO | BridgeBio Pharma, Inc. | $13.2M | 0.6% | +87% | 36.9 |
| 42 |  $SRPT | Sarepta Therapeutics, Inc. | $13.1M | 0.6% | +179% | 47.3 |
| 43 |  $CTMX | CytomX Therapeutics, Inc. | $12.6M | 0.6% | -1% | 8.7 |
| 44 |  $VOR | Vor Biopharma Inc. | $12.5M | 0.6% | NEW | — |
| 45 | — | SPDR SERIES TRUST - ST STR BLO 1 ETF | $12.4M | 0.6% | +0% | — |
| 46 |  $EQ | Equillium, Inc. | $12.0M | 0.6% | +1% | 11.7 |
| 47 |  $ANL | Adlai Nortye Group Ltd. | $11.7M | 0.6% | +763% | — |
| 48 |  $CLYM | Climb Bio, Inc. | $10.7M | 0.5% | +38% | — |
| 49 | — | SPDR SERIES TRUST - ST STR SP BIOT | $10.7M | — | +349% | — |
| 50 | — | HELIX ACQUISITION CORP III - USD CL A ORD SHS | $10.6M | 0.5% | +0% | — |
| 51 |  $ZURA | Zura Bio Ltd | $10.4M | 0.5% | +179% | — |
| 52 |  $OKUR | OnKure Therapeutics, Inc. | $10.2M | 0.5% | -8% | — |
| 53 |  $MAZE | Maze Therapeutics, Inc. | $10.1M | 0.5% | +577% | 10.3 |
| 54 |  $XENE | Xenon Pharmaceuticals Inc. | $10.1M | 0.5% | -27% | 24 |
| 55 |  $TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $9.4M | 0.4% | +4% | — |
| 56 |  $URGN | UroGen Pharma Ltd. | $9.3M | 0.4% | -36% | — |
| 57 | — | FAETH THERAPEUTICS INC - COM NEW | $9.0M | 0.4% | NEW | — |
| 58 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $8.9M | 0.4% | -51% | 8.7 |
| 59 |  $DBVT | DBV Technologies S.A. | $8.7M | 0.4% | -48% | — |
| 60 |  $SVRA | Savara Inc | $8.6M | 0.4% | -4% | — |
| 61 |  $PCVX | Vaxcyte, Inc. | $8.5M | 0.4% | -44% | — |
| 62 |  $CGON | CG Oncology, Inc. | $8.4M | 0.4% | -36% | 27 |
| 63 |  $MLYS | Mineralys Therapeutics, Inc. | $8.1M | 0.4% | +93% | — |
| 64 |  $ASND | Ascendis Pharma A/S | $7.6M | 0.4% | +14% | 44.8 |
| 65 |  $AMAN | Amanat Acquisition Corp. | $7.6M | 0.4% | NEW | — |
| 66 |  $NRIX | Nurix Therapeutics, Inc. | $7.6M | 0.4% | +459% | 6.4 |
| 67 |  $BHVN | Biohaven Ltd. | $7.5M | 0.3% | +1020% | — |
| 68 |  $PRME | Prime Medicine, Inc. | $7.4M | 0.3% | +1% | 30.7 |
| 69 |  $FRNM | Freenome, Inc. | $7.3M | 0.3% | +35% | — |
| 70 |  $IRD | Opus Genetics, Inc. | $7.3M | 0.3% | -4% | — |
| 71 |  $LXEO | Lexeo Therapeutics, Inc. | $7.3M | 0.3% | +7% | — |
| 72 |  $DMRA | Damora Therapeutics, Inc. | $7.3M | 0.3% | +0% | — |
| 73 |  $REPL | Replimune Group, Inc. | $7.3M | 0.3% | -59% | — |
| 74 |  $LONA | LeonaBio, Inc. | $7.1M | 0.3% | +7% | — |
| 75 |  $KRRO | Korro Bio, Inc. | $7.1M | 0.3% | +0% | 14.1 |
| 76 |  $RACC | Research Alliance Corp III | $7.0M | 0.3% | NEW | — |
| 77 |  $IFRX | InflaRx N.V. | $6.7M | 0.3% | +1795% | — |
| 78 |  $RLAY | Relay Therapeutics, Inc. | $6.7M | 0.3% | NEW | 19.5 |
| 79 |  $JANX | Janux Therapeutics, Inc. | $6.5M | 0.3% | +41% | 30.1 |
| 80 |  $PLRX | PLIANT THERAPEUTICS, INC. | $6.3M | 0.3% | +113% | — |
| 81 |  $WHWK | Whitehawk Therapeutics, Inc. | $6.1M | 0.3% | +944% | 26.4 |
| 82 |  $KRYS | Krystal Biotech, Inc. | $6.1M | 0.3% | -18% | 79.2 |
| 83 |  $ABUS | Arbutus Biopharma Corp | $6.1M | 0.3% | -60% | 7.3 |
| 84 |  $PFE | PFIZER INC | $6.1M | 0.3% | +226% | 62 |
| 85 |  $BHF | Brighthouse Financial, Inc. | $6.0M | 0.3% | +0% | 68.4 |
| 86 | $ABVXCALL | Abivax S.A. | $5.9M | — | +1% | — |
| 87 |  $EWTX | Edgewise Therapeutics, Inc. | $5.8M | 0.3% | +58% | — |
| 88 |  $ALEC | Alector, Inc. | $5.8M | 0.3% | +175% | 10.9 |
| 89 |  $FULC | Fulcrum Therapeutics, Inc. | $5.7M | 0.3% | +1099% | 32.9 |
| 90 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $5.7M | 0.3% | -1% | 38.7 |
| 91 |  $ABOS | Acumen Pharmaceuticals, Inc. | $5.6M | 0.3% | -2% | — |
| 92 |  $OACC | Oaktree Acquisition Corp. III Life Sciences | $5.6M | 0.3% | +0% | — |
| 93 |  $GMED | GLOBUS MEDICAL INC | $5.5M | 0.3% | +249% | 79.5 |
| 94 |  $GLUE | Monte Rosa Therapeutics, Inc. | $5.2M | 0.3% | +0% | 30.3 |
| 95 | — | DISCIPLINED GROWTH - UNIT 99/99/9999 | $5.0M | 0.2% | NEW | — |
| 96 | — | BHAV ACQUISITION CORP - UNIT 03/18/2031 | $5.0M | 0.2% | +0% | — |
| 97 | — | BRIDGEBIO PHARMA INC - NOTE 1.750% 3/0 | $5.0M | 0.2% | +0% | — |
| 98 | $BBIO | BridgeBio Pharma, Inc. | $4.9M | 0.2% | +0% | 36.9 |
| 99 |  $DHR | DANAHER CORP /DE/ | $4.9M | 0.2% | -16% | 64.8 |
| 100 |  $BOLD | Boundless Bio, Inc. | $4.9M | 0.2% | NEW | — |
| 101 |  $AVLN | Avalyn Pharma Inc. | $4.8M | 0.2% | NEW | — |
| 102 |  $SPRY | ARS Pharmaceuticals, Inc. | $4.8M | 0.2% | -56% | 20.3 |
| 103 |  $ATAI.R1840904 | Atai Beckley N.V. | $4.8M | 0.2% | +0% | — |
| 104 |  $PRLD | Prelude Therapeutics Inc | $4.8M | 0.2% | +489% | 21.5 |
| 105 |  $JATT | JATT II Acquisition Corp. | $4.7M | 0.2% | NEW | — |
| 106 |  $RNTX | Rein Therapeutics, Inc. | $4.7M | 0.2% | NEW | — |
| 107 |  $PEPG | PepGen Inc. | $4.7M | 0.2% | +61% | — |
| 108 |  $CTNM | Contineum Therapeutics, Inc. | $4.6M | 0.2% | +1% | — |
| 109 |  $CATX | Perspective Therapeutics, Inc. | $4.1M | 0.2% | +61% | — |
| 110 |  $APGE | Apogee Therapeutics, Inc. | $4.1M | 0.2% | NEW | — |
| 111 |  $NAMS | NewAmsterdam Pharma Co N.V. | $4.0M | 0.2% | +0% | — |
| 112 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $4.0M | 0.2% | +27% | — |
| 113 |  $BIIB | BIOGEN INC. | $3.9M | 0.2% | +63% | 64.7 |
| 114 |  $XNCR | Xencor Inc | $3.7M | 0.2% | +148% | 11.6 |
| 115 |  $SLN | Silence Therapeutics plc | $3.7M | 0.2% | +97% | — |
| 116 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $3.7M | 0.2% | +16% | — |
| 117 |  $PHVS | Pharvaris N.V. | $3.6M | 0.2% | +0% | — |
| 118 |  $ENGN | enGene Therapeutics Inc. | $3.6M | 0.2% | +1475% | — |
| 119 |  $PALI | PALISADE BIO, INC. | $3.6M | 0.2% | -24% | — |
| 120 |  $TARA | Protara Therapeutics, Inc. | $3.6M | 0.2% | +0% | — |
| 121 | $BBIO | BridgeBio Pharma, Inc. | $3.5M | 0.2% | +0% | 36.9 |
| 122 |  $SGMT | Sagimet Biosciences Inc. | $3.4M | 0.2% | NEW | — |
| 123 |  $ONC | BeOne Medicines Ltd. | $3.3M | 0.2% | +0% | — |
| 124 |  $IVVD | Invivyd, Inc. | $3.3M | 0.2% | -0% | 29.7 |
| 125 |  $TENX | TENAX THERAPEUTICS, INC. | $3.2M | 0.1% | +3% | — |
| 126 |  $ZNTL | Zentalis Pharmaceuticals, Inc. | $3.2M | 0.1% | +351% | 11.6 |
| 127 |  $RLMD | RELMADA THERAPEUTICS, INC. | $3.1M | 0.1% | +0% | — |
| 128 |  $DCTH | DELCATH SYSTEMS, INC. | $2.8M | 0.1% | +0% | 54.7 |
| 129 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $2.8M | 0.1% | +169% | 58.2 |
| 130 |  $SMMT | Summit Therapeutics Inc. | $2.8M | 0.1% | +109% | — |
| 131 |  $KROS | Keros Therapeutics, Inc. | $2.6M | 0.1% | +154% | 27.3 |
| 132 |  $ELDN | Eledon Pharmaceuticals, Inc. | $2.6M | 0.1% | -34% | — |
| 133 |  $SNY | Sanofi | $2.4M | 0.1% | -82% | — |
| 134 |  $AEXA | American Exceptionalism Acquisition Corp. A | $2.4M | 0.1% | -43% | — |
| 135 |  $TNGX | Tango Therapeutics, Inc. | $2.4M | 0.1% | +54% | 17.6 |
| 136 |  $ISRG | INTUITIVE SURGICAL INC | $2.4M | 0.1% | +230% | 79.9 |
| 137 |  $INO | INOVIO PHARMACEUTICALS, INC. | $2.4M | 0.1% | +46% | 8.3 |
| 138 |  $OABI | OmniAb, Inc. | $2.3M | 0.1% | +34% | 33 |
| 139 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $2.2M | 0.1% | +0% | 13.6 |
| 140 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $2.1M | 0.1% | -11% | — |
| 141 |  $ORKA | Oruka Therapeutics, Inc. | $2.0M | 0.1% | +0% | — |
| 142 |  $YARW | Yarrow Bioscience, Inc. | $1.9M | 0.1% | +177% | — |
| 143 |  $MCK | MCKESSON CORP | $1.9M | 0.1% | +108% | 63.4 |
| 144 |  $LXRX | LEXICON PHARMACEUTICALS, INC. | $1.8M | 0.1% | +0% | 33.7 |
| 145 |  $CRVS | Corvus Pharmaceuticals, Inc. | $1.7M | 0.1% | +33% | — |
| 146 |  $CUE | Cue Biopharma, Inc. | $1.7M | 0.1% | NEW | 28.9 |
| 147 |  $MSLE | Satellos Bioscience Inc. | $1.7M | 0.1% | +0% | — |
| 148 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $1.7M | 0.1% | +0% | — |
| 149 |  $CNTB | Connect Biopharma Holdings Ltd | $1.7M | 0.1% | -6% | — |
| 150 |  $CCII | Cohen Circle Acquisition Corp. II | $1.6M | 0.1% | +0% | — |
| 151 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $1.5M | 0.1% | +1% | — |
| 152 |  $TRAX | First Tracks Biotherapeutics, Inc. | $1.4M | 0.1% | NEW | — |
| 153 |  $EVMN | Evommune, Inc. | $1.4M | 0.1% | -43% | 14.9 |
| 154 |  $CCCC | C4 Therapeutics, Inc. | $1.4M | 0.1% | +579% | 18.2 |
| 155 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $1.3M | 0.1% | +27% | 53.2 |
| 156 |  $SUPN | SUPERNUS PHARMACEUTICALS, INC. | $1.3M | 0.1% | -6% | 41.9 |
| 157 |  $NVO | NOVO NORDISK A S | $1.3M | 0.1% | -18% | — |
| 158 |  $AVTR | Avantor, Inc. | $1.3M | 0.1% | +63% | 39.6 |
| 159 |  $INM | InMed Pharmaceuticals Inc. | $1.2M | 0.1% | NEW | 13.1 |
| 160 |  $PMN | ProMIS Neurosciences Inc. | $1.2M | 0.1% | -3% | — |
| 161 | — | ARROWHEAD PHARMACEUTICALS IN - NOTE 1/1 | $1.2M | 0.1% | +0% | — |
| 162 |  $ARTV | Artiva Biotherapeutics, Inc. | $1.2M | 0.1% | NEW | 9.7 |
| 163 |  $TNYA | Tenaya Therapeutics, Inc. | $1.1M | 0.1% | +3% | — |
| 164 |  $ALXO | ALX ONCOLOGY HOLDINGS INC | $1.1M | 0.1% | NEW | — |
| 165 |  $ARE | ALEXANDRIA REAL ESTATE EQUITIES, INC. | $1.0M | 0.1% | +0% | 43 |
| 166 |  $RNAC | Cartesian Therapeutics, Inc. | $1.0M | 0.1% | NEW | 8 |
| 167 |  $CYCN | Cyclerion Therapeutics, Inc. | $1.0M | 0.1% | NEW | — |
| 168 |  $EA | ELECTRONIC ARTS INC. | $1.0M | 0.1% | +0% | 62.9 |
| 169 |  $TVTX | Travere Therapeutics, Inc. | $1.0M | 0.1% | NEW | 56.6 |
| 170 |  $BNTX | BioNTech SE | $986,330 | 0.1% | +6% | — |
| 171 |  $ACAD | ACADIA PHARMACEUTICALS INC | $985,562 | 0.1% | NEW | 67.8 |
| 172 |  $DYN | Dyne Therapeutics, Inc. | $951,054 | 0.0% | -10% | — |
| 173 |  $MPLT | MapLight Therapeutics, Inc. | $949,652 | 0.0% | -93% | — |
| 174 |  $GPCR | Structure Therapeutics Inc. | $939,225 | 0.0% | NEW | — |
| 175 |  $KVACCALL | Keen Vision Acquisition Corp. | $930,000 | — | +0% | — |
| 176 |  $WVE | Wave Life Sciences, Inc. | $929,600 | 0.0% | +256% | 7.5 |
| 177 |  $AURA | Aura Biosciences, Inc. | $924,079 | 0.0% | NEW | — |
| 178 | — | CHURCHILL CAP CORP XI - CL A ORD SHS | $872,500 | 0.0% | NEW | — |
| 179 |  $KZIA | KAZIA THERAPEUTICS LTD | $866,624 | 0.0% | NEW | — |
| 180 |  $NUVL | Nuvalent, Inc. | $857,337 | 0.0% | +0% | — |
| 181 |  $LRMR | Larimar Therapeutics, Inc. | $831,872 | 0.0% | +417% | — |
| 182 |  $VERA | Vera Therapeutics, Inc. | $786,197 | 0.0% | +14% | — |
| 183 |  $ADGM | Adagio Medical Holdings, Inc. | $785,469 | 0.0% | +0% | — |
| 184 |  $RNA.R1599901 | Avidity Biosciences, Inc. | $775,904 | 0.0% | +0% | — |
| 185 |  $TXMD | TherapeuticsMD, Inc. | $756,808 | 0.0% | +64% | — |
| 186 |  $IDYA | IDEAYA Biosciences, Inc. | $745,400 | 0.0% | +0% | 36.1 |
| 187 |  $SIBN | SI-BONE, Inc. | $734,400 | 0.0% | +258% | 42.7 |
| 188 | $AMLXPUT | Amylyx Pharmaceuticals, Inc. | $720,196 | — | NEW | 8.7 |
| 189 |  $RPRX | Royalty Pharma plc | $700,875 | 0.0% | +150% | — |
| 190 |  $EOLS | Evolus, Inc. | $694,000 | 0.0% | +79% | 39 |
| 191 |  $RARECALL | Ultragenyx Pharmaceutical Inc. | $667,800 | — | +0% | 34.2 |
| 192 |  $IBIO | iBio, Inc. | $657,179 | 0.0% | -20% | 10.4 |
| 193 |  $FWRD | FORWARD AIR CORP | $651,736 | 0.0% | -38% | 41.7 |
| 194 |  $GERN | GERON CORP | $647,446 | 0.0% | +153% | — |
| 195 |  $SYK | STRYKER CORP | $629,680 | 0.0% | NEW | 72.1 |
| 196 | $NVOCALL | NOVO NORDISK A S | $623,220 | — | +0% | — |
| 197 |  $IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $607,734 | 0.0% | NEW | 36.8 |
| 198 |  $MGNX | MACROGENICS INC | $599,778 | 0.0% | +225% | 39.6 |
| 199 |  $GILD | GILEAD SCIENCES, INC. | $587,228 | 0.0% | -27% | 57.4 |
| 200 |  $NTRA | Natera, Inc. | $582,803 | 0.0% | +0% | 53.5 |
| 201 |  $SPTX | Seaport Therapeutics, Inc. | $564,720 | 0.0% | NEW | — |
| 202 | $CRBPCALL | Corbus Pharmaceuticals Holdings, Inc. | $562,800 | — | +71% | — |
| 203 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $561,884 | 0.0% | +3% | 41.5 |
| 204 |  $HELP | CYBIN INC. | $537,248 | 0.0% | +160% | — |
| 205 |  $BNTC | Benitec Biopharma Inc. | $535,200 | 0.0% | +129% | — |
| 206 |  $PYPD | PolyPid Ltd. | $528,066 | 0.0% | +0% | — |
| 207 |  $LUNG | Pulmonx Corp | $525,846 | 0.0% | +8% | 23.4 |
| 208 |  $MLTX | MoonLake Immunotherapeutics | $525,690 | 0.0% | -94% | — |
| 209 |  $GTERA | Globa Terra Acquisition Corp | $519,500 | 0.0% | +0% | — |
| 210 |  $TRAW | Traws Pharma, Inc. | $504,065 | 0.0% | +288% | — |
| 211 |  $WT | WisdomTree, Inc. | $503,500 | 0.0% | +0% | 59.9 |
| 212 |  $TECX | Tectonic Therapeutic, Inc. | $498,472 | 0.0% | +12% | — |
| 213 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $480,570 | 0.0% | +0% | 40.7 |
| 214 |  $ARVN | ARVINAS, INC. | $478,581 | 0.0% | +0% | 36.6 |
| 215 |  $KIDS | ORTHOPEDIATRICS CORP | $478,250 | 0.0% | +26% | 37.8 |
| 216 |  $COGT | Cogent Biosciences, Inc. | $472,140 | 0.0% | NEW | — |
| 217 |  $PHAT | Phathom Pharmaceuticals, Inc. | $465,465 | 0.0% | +0% | 40.9 |
| 218 |  $MIRM | Mirum Pharmaceuticals, Inc. | $456,573 | 0.0% | -37% | 35 |
| 219 |  $KPRX | KIORA PHARMACEUTICALS INC | $441,685 | 0.0% | +0% | — |
| 220 |  $KURA | Kura Oncology, Inc. | $438,800 | 0.0% | +0% | 27.6 |
| 221 |  $CNTX | Context Therapeutics Inc. | $415,962 | 0.0% | +114% | — |
| 222 | — | ISHARES TR - 0-5 YR TIPS ETF | $408,640 | 0.0% | NEW | — |
| 223 |  $KLRS | Kalaris Therapeutics, Inc. | $407,000 | 0.0% | +0% | — |
| 224 |  $BCAX | Bicara Therapeutics Inc. | $406,901 | 0.0% | +0% | — |
| 225 |  $MRK | Merck & Co., Inc. | $403,490 | 0.0% | +0% | 59.9 |
| 226 |  $NMRA | Neumora Therapeutics, Inc. | $357,000 | 0.0% | +534% | — |
| 227 |  $IRTC | iRhythm Holdings, Inc. | $356,850 | 0.0% | NEW | 54.8 |
| 228 |  $ACHV | ACHIEVE LIFE SCIENCES, INC. | $351,314 | 0.0% | +13% | — |
| 229 |  $BABA | Alibaba Group Holding Ltd | $343,416 | 0.0% | +0% | — |
| 230 |  $WW | WW INTERNATIONAL, INC. | $340,374 | 0.0% | -63% | 27.4 |
| 231 |  $CNSP | CNS Pharmaceuticals, Inc. | $334,600 | 0.0% | NEW | — |
| 232 |  $CBIO | CRESCENT BIOPHARMA, INC. | $328,950 | 0.0% | -64% | 9.6 |
| 233 |  $BSX | BOSTON SCIENTIFIC CORP | $320,100 | 0.0% | -25% | 77.5 |
| 234 |  $ALT | Altimmune, Inc. | $312,582 | 0.0% | NEW | 8 |
| 235 |  $VSTM | Verastem, Inc. | $289,556 | 0.0% | +7% | 29.7 |
| 236 |  $ANTX | AN2 Therapeutics, Inc. | $284,631 | 0.0% | +324% | — |
| 237 |  $DERM | Journey Medical Corp | $279,780 | 0.0% | NEW | 16.5 |
| 238 |  $PCAP | ProCap Acquisition Corp | $279,368 | 0.0% | +0% | — |
| 239 |  $PMVP | PMV Pharmaceuticals, Inc. | $269,351 | 0.0% | -13% | — |
| 240 |  $CMPX | Compass Therapeutics, Inc. | $267,469 | 0.0% | -12% | 28.1 |
| 241 |  $JD | JD.com, Inc. | $254,800 | 0.0% | +0% | — |
| 242 |  $RZLT | Rezolute, Inc. | $253,131 | 0.0% | -17% | — |
| 243 |  $ANAB | ANAPTYSBIO, INC | $249,615 | 0.0% | +0% | 48.4 |
| 244 |  $NGNE | Neurogene Inc. | $245,310 | 0.0% | NEW | 27.4 |
| 245 | — | ISHARES TR - U.S. MED DVC ETF | $242,109 | 0.0% | NEW | — |
| 246 |  $RXST | RxSight, Inc. | $241,000 | 0.0% | +16% | 28.1 |
| 247 |  $COYA | Coya Therapeutics, Inc. | $239,265 | 0.0% | +0% | — |
| 248 |  $BCYC | BICYCLE THERAPEUTICS PLC | $214,705 | 0.0% | -29% | — |
| 249 | — | CANTOR EQUITY PARTNERS VI IN - CL A ORD SHS | $207,400 | 0.0% | +0% | — |
| 250 |  $SCYX | SCYNEXIS INC | $201,005 | 0.0% | NEW | — |
| 251 |  $PSNL | Personalis, Inc. | $201,000 | 0.0% | -40% | 11.3 |
| 252 |  $QCLS | Q/C TECHNOLOGIES, INC. | $195,000 | 0.0% | +0% | — |
| 253 |  $CABA | Cabaletta Bio, Inc. | $155,500 | 0.0% | NEW | — |
| 254 |  $RXRX | RECURSION PHARMACEUTICALS, INC. | $150,470 | 0.0% | +17% | 23.3 |
| 255 |  $OGN | Organon & Co. | $135,400 | 0.0% | +0% | 50.5 |
| 256 |  $MIST | Milestone Pharmaceuticals Inc. | $134,000 | 0.0% | +0% | — |
| 257 |  $NEUP | Neuphoria Therapeutics Inc. | $131,100 | 0.0% | +0% | — |
| 258 |  $STIM | Neuronetics, Inc. | $130,000 | 0.0% | +0% | 36.9 |
| 259 |  $CMMB | Chemomab Therapeutics Ltd. | $129,600 | 0.0% | +0% | — |
| 260 |  $STICALL | Solidion Technology Inc. | $125,415 | — | +0% | — |
| 261 |  $VYGR | Voyager Therapeutics, Inc. | $122,500 | 0.0% | +0% | 8.1 |
| 262 |  $TRDA | Entrada Therapeutics, Inc. | $114,080 | 0.0% | -49% | 7.3 |
| 263 |  $VERU | VERU INC. | $109,550 | 0.0% | +0% | — |
| 264 |  $CAES | Cantor Equity Partners VII, Inc. | $100,900 | 0.0% | NEW | — |
| 265 |  $CLNN | Clene Inc. | $92,325 | 0.0% | NEW | — |
| 266 |  $VTGN | Vistagen Therapeutics, Inc. | $79,358 | 0.0% | -53% | — |
| 267 |  $LGVN | Longeveron Inc. | $76,209 | 0.0% | -46% | — |
| 268 |  $BMEA | Biomea Fusion, Inc. | $63,827 | 0.0% | +0% | — |
| 269 |  $LITS | Lite Strategy, Inc. | $62,070 | 0.0% | +0% | — |
| 270 |  $JSPR | Jasper Therapeutics, Inc. | $58,940 | 0.0% | +0% | — |
| 271 |  $ARDX | ARDELYX, INC. | $56,100 | 0.0% | -54% | 41.9 |
| 272 |  $GOSS | Gossamer Bio, Inc. | $34,983 | 0.0% | -26% | 8.2 |
| 273 |  $ATYR | aTYR PHARMA INC | $30,249 | 0.0% | +0% | — |
| 274 | — | A SPAC III ACQUISITION CORP - RIGHT 01/02/2026 | $19,114 | 0.0% | +0% | — |
| 275 |  $PRQR | ProQR Therapeutics N.V. | $18,600 | 0.0% | +0% | — |
| 276 |  $BSAA | BEST SPAC I Acquisition Corp. | $16,560 | 0.0% | +0% | — |
| 277 |  $CHRS | Coherus Oncology, Inc. | $14,512 | 0.0% | +0% | 5 |
New Positions (43)
$EDIT Editas Medicine, Inc.$28.8M$SPYPUT SPDR S&P 500 ETF TRUST$18.7M$VOR Vor Biopharma Inc.$12.5M FAETH THERAPEUTICS INC - COM NEW$9.0M
$AMAN Amanat Acquisition Corp.$7.6M$RACC Research Alliance Corp III$7.0M$RLAY Relay Therapeutics, Inc.$6.7M DISCIPLINED GROWTH - UNIT 99/99/9999$5.0M
$BOLD Boundless Bio, Inc.$4.9M$AVLN Avalyn Pharma Inc.$4.8M$JATT JATT II Acquisition Corp.$4.7M$RNTX Rein Therapeutics, Inc.$4.7M$APGE Apogee Therapeutics, Inc.$4.1M$SGMT Sagimet Biosciences Inc.$3.4M$CUE Cue Biopharma, Inc.$1.7MExited Positions (76)
$TERN Terns Pharmaceuticals, Inc.
$BEAM Beam Therapeutics Inc.
$SRRK Scholar Rock Holding Corp$TERNCALL Terns Pharmaceuticals, Inc.
$VRTX VERTEX PHARMACEUTICALS INC / MA
$VRDN Viridian Therapeutics, Inc.\DE
$LLY ELI LILLY & Co
$DNTH Dianthus Therapeutics, Inc. /DE/
$BLTE BELITE BIO, INC
$LQDAPUT Liquidia Corp
$ACLX Arcellx, Inc.
$AVBP ArriVent BioPharma, Inc.
$APLS Apellis Pharmaceuticals, Inc.
$MASI MASIMO CORP
$TFX TELEFLEX INCBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for ADAR1 Capital Management, LLC including:
Full 13F portfolio with all holdings
Quarter-over-quarter position changes
Accumulation & distribution patterns
Sector allocation breakdown
Historical portfolio evolution
New positions & complete exits
Concentration analysis
Peer comparison with similar funds
AI-powered portfolio insights
Track ADAR1 Capital Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for ADAR1 Capital Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
Passwordless sign-in · Payments by Stripe · Auth by Clerk
AI-Powered Hedge Fund Analysis: ADAR1 Capital Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For ADAR1 Capital Management, LLC (SEC CIK: 1940272), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in ADAR1 Capital Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.